WCM Investment Management LLC Has $20.58 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

WCM Investment Management LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 4,288.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 144,803 shares of the life sciences company's stock after acquiring an additional 141,503 shares during the quarter. WCM Investment Management LLC owned about 0.09% of Illumina worth $20,581,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Illumina in the 3rd quarter valued at about $30,000. State of Wyoming purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $32,000. Quent Capital LLC raised its stake in shares of Illumina by 71.2% in the 3rd quarter. Quent Capital LLC now owns 250 shares of the life sciences company's stock valued at $34,000 after acquiring an additional 104 shares during the period. VisionPoint Advisory Group LLC raised its stake in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after acquiring an additional 193 shares during the period. Finally, ST Germain D J Co. Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $36,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the firm's stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Stephens reissued an "overweight" rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday. OTR Global reaffirmed a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Barclays upped their target price on shares of Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research note on Wednesday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Finally, StockNews.com raised shares of Illumina from a "hold" rating to a "buy" rating in a research note on Friday, February 16th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $167.70.

Illumina Price Performance

Shares of ILMN traded down $3.63 during trading hours on Friday, reaching $127.07. The company had a trading volume of 1,629,452 shares, compared to its average volume of 1,567,804. The firm has a 50 day simple moving average of $135.77 and a 200-day simple moving average of $128.43. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $20.24 billion, a price-to-earnings ratio of -17.31 and a beta of 1.19. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $232.88.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the firm posted $0.14 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.